References
- Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–350.
- Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011 ;364: 1728–1737.
- Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301.
- Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25: 2267–2294.
- FRiSC Guidelines on management of bisphosphonate associated atypical femoral subtrochanteric and shaft fractures. Fracture Reduction South Central Policy Group. 2011. Available from: http://www.ndorms.ox.ac.uk/downloads/friscy.atypical-1–6.pdf. Accessed July 21, 2013.